Summit Trail Advisors’s Integra LifeSciences IART Stock Holding History

Summit Trail Advisors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.15M	Buy	121,616 +52,297	+75%	+$574K	0.02%	872
2025 Q4	$861K	Buy	69,319 +17,952	+35%	+$239K	0.01%	891
2025 Q3	$736K	Sell	51,367 -41,577	-45%	-$570K	0.01%	966
2025 Q2	$1.14M	Buy	+92,944	New	+$1.35M	0.02%	427
2018 Q1	–	Sell	-5	Closed	–	–	1001
2017 Q4	$0	Buy	+5	New	+$245	﹤0.01%	2026

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Summit Trail Advisors's IART Position: Q1 2026 in Review

Summit Trail Advisors increased its Integra LifeSciences (IART) stake by 75% in Q1 2026, buying an estimated $574K and bringing the position to 121,616 shares worth $1.15M. The position accounts for 0.02% of the portfolio, ranked #872.

Summit Trail Advisors first reported a position in IART in Q4 2017 and has held it in 5 quarters since. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

Summit Trail Advisors held 121,616 shares of Integra LifeSciences worth $1.15M as of Q1 2026.
Summit Trail Advisors bought 52,297 Integra LifeSciences shares in Q1 2026, an estimated $574K.
Integra LifeSciences made up 0.02% of Summit Trail Advisors's portfolio in Q1 2026, its #872 holding.
Summit Trail Advisors first reported a position in Integra LifeSciences in Q4 2017 and has held it in 5 quarters since.
201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.